Literature DB >> 17343573

Ovarian tumors of borderline malignancy: a review of 247 patients from 1991 to 2004.

H F Wong1, J J H Low, Y Chua, I Busmanis, E H Tay, T H Ho.   

Abstract

Borderline ovarian tumors account for 15% of epithelial ovarian cancers and are different from invasive malignant carcinoma. Majority are early stage, occurring in women in the reproductive age group, where fertility is important. We reviewed retrospectively 247 such cases treated at the Gynaecological-Oncology Unit, KK Women's and Children's Hospital, between January 1991 and December 2004. The mean age was 38 years (16-89 years). Majority of the cases (92%) were FIGO stage I (Ia, 75%; Ib, 1%; and Ic, 16%). Seven (3.5%) patients were diagnosed as having stage II disease, six (2.5%) as stage IIIa, two (1%) as stage IIIb, and four (2%) as stage IIIc. Histological origin was as follows: mucinous (68%), serous (26%), endometrioid (2.6%), and clear cell (1.2%). Primary surgical procedures undertaken were as follows: hysterectomy with bilateral salpingo-oophorectomy (52%), unilateral salpingo-oophorectomy (33%), or ovarian cystectomy (15%). Adjuvant chemotherapy was administered in 13 patients (5.2% of cases), of which 4 patients were given chemotherapy only because of synchronous malignancies. There were six recurrences (2.4% of cases). Overall mean time to recurrence was 59 months. Recurrence rate for patients who underwent a primary pelvic clearance was 1.6% compared to fertility-sparing conservative surgery (3.3%; although P= 0.683). No significant difference was noted in recurrence and mortality between staged versus unstaged procedures. The overall survival rate was 98.0%. There were a total of five deaths (2.8%): three (1.5%) from invasive ovarian/peritoneal carcinoma and two from synchronous uterine malignancies. It appears that surgical resection is the mainstay of treatment, with conservative surgery where fertility is desired or pelvic clearance if the family is complete. Surgical staging is important to identify invasive extraovarian implants that portend an adverse prognosis. The role of adjuvant chemotherapy is not established.

Entities:  

Mesh:

Year:  2007        PMID: 17343573     DOI: 10.1111/j.1525-1438.2007.00864.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  16 in total

1.  Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors.

Authors:  Hugo Arias-Pulido; Harriet O Smith; Nancy E Joste; Therese Bocklage; Clifford R Qualls; Allison Chavez; Eric R Prossnitz; Claire F Verschraegen
Journal:  Gynecol Oncol       Date:  2009-06-27       Impact factor: 5.482

2.  Management of a suspicious adnexal mass: a clinical practice guideline.

Authors:  J E Dodge; A L Covens; C Lacchetti; L M Elit; T Le; M Devries-Aboud; M Fung-Kee-Fung
Journal:  Curr Oncol       Date:  2012-08       Impact factor: 3.677

Review 3.  Interventions for the treatment of borderline ovarian tumours.

Authors:  Olusola Faluyi; Melanie Mackean; Charlie Gourley; Andrew Bryant; Heather O Dickinson
Journal:  Cochrane Database Syst Rev       Date:  2010-09-08

4.  A meta-analysis on the impact of platinum-based adjuvant treatment on the outcome of borderline ovarian tumors with invasive implants.

Authors:  Ines Vasconcelos; Jessica Olschewski; Ioana Braicu; Jalid Sehouli
Journal:  Oncologist       Date:  2015-01-19

5.  Clear Cell Borderline Ovarian Tumor: Clinical Characteristics, Prognosis, and Management.

Authors:  Giulio Ricotta; Amandine Maulard; Massimo Candiani; Catherine Genestie; Patricia Pautier; Alexandra Leary; Cyrus Chargari; Giorgia Mangili; Philippe Morice; Sébastien Gouy
Journal:  Ann Surg Oncol       Date:  2021-10-01       Impact factor: 5.344

6.  Major Clinical Impact of Platinum-Based Chemotherapy in a Patient with a Borderline Ovarian Cancer.

Authors:  Jian Chen; Maurie Markman
Journal:  Case Rep Oncol       Date:  2009-09-22

7.  Frequency of mutations and polymorphisms in borderline ovarian tumors of known cancer genes.

Authors:  Katherine Stemke-Hale; Kristy Shipman; Isidora Kitsou-Mylona; David G de Castro; Vicky Hird; Robert Brown; James Flanagan; Hani Gabra; Gordon B Mills; Roshan Agarwal; Mona El-Bahrawy
Journal:  Mod Pathol       Date:  2012-11-23       Impact factor: 7.842

8.  A retrospective analysis of clinicopathological and prognostic characteristics of ovarian tumors in the State of Espírito Santo, Brazil.

Authors:  Marcela F Paes; Renata D Daltoé; Klesia P Madeira; Lucas Cd Rezende; Gabriela M Sirtoli; Alice L Herlinger; Leticia S Souza; Luciana B Coitinho; Débora Silva; Murilo F Cerri; Ana Cristina N Chiaradia; Alex A Carvalho; Ian V Silva; Leticia Ba Rangel
Journal:  J Ovarian Res       Date:  2011-08-09       Impact factor: 4.234

9.  Nationwide population-based study of prevalence and trend of borderline ovarian tumors in the Republic of Korea.

Authors:  Yung-Taek Ouh; Dongwoo Kang; Hoseob Kim; Jae Kwan Lee; Jin Hwa Hong
Journal:  Sci Rep       Date:  2021-05-27       Impact factor: 4.379

10.  Histologic distribution of borderline ovarian tumors worldwide: a systematic review.

Authors:  Taejong Song; Yoo-Young Lee; Chel Hun Choi; Tae-Joong Kim; Jeong-Won Lee; Duk-Soo Bae; Byoung-Gie Kim
Journal:  J Gynecol Oncol       Date:  2013-01-08       Impact factor: 4.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.